Search research articles
Contact Us
Filters
Showing results (21-30 of 27) with videos related to
Page
of 3
Sort By:
You have reached the last page of results.
This site can display upto 27 results.
ESMO Open
|
October 1, 2025
Pembrolizumab with trastuzumab and chemotherapy for HER2-positive advanced gastric cancer: health-related quality-of-life analysis from the randomized KEYNOTE-811 trial
Y Y Janjigian, A Kawazoe, J Xu, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 25, 2019
Continuation versus discontinuation of first-line chemotherapy in patients with metastatic squamous cell oesophageal cancer: A randomised phase II trial (E-DIS)
A Adenis, J Bennouna, P L Etienne, et al.
ESMO Open
|
February 26, 2026
Surrogate endpoints for survival in KEYNOTE-585: neoadjuvant/adjuvant pembrolizumab plus chemotherapy versus placebo plus chemotherapy for gastric or gastroesophageal junction adenocarcinoma
K Shitara, Y-J Bang, L S Wyrwicz, et al.
ESMO Open
|
November 19, 2025
Pembrolizumab plus chemotherapy versus chemotherapy for advanced esophageal cancer: 5-year extended follow-up for the randomized phase III KEYNOTE-590 study
J-P Metges, K Kato, J-M Sun, et al.
ESMO Open
|
December 3, 2025
Streptozotocin plus 5-fluorouracil followed by everolimus or the reverse sequence in patients with advanced pancreatic neuroendocrine tumors (SEQTOR-GETNE phase III study): a randomized clinical trial
J Capdevila, S Tafuto, M Krogh, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 5, 2017
Clinical validation of a prognostic tool in a population of outpatients treated for incurable cancer undergoing anticancer therapy: PRONOPALL study
H Bourgeois, F Grudé, P Solal-Céligny, et al.
Oncologie (Paris, France)
|
July 21, 2015
Evaluation in usual practice of the bevacizumab-FOLFIRI combination for the first-line treatment of patients with unresectable metastatic colorectal cancer treated in 2006: focus on resected patients and oncogeriatrics: AVASTIN OUEST cohort of the Observatory of Cancer of the Brittany and Pays de la Loire Areas (<i>Observatoire dédié au Cancer Bretagne / Pays de la Loire</i>)
J P Metges, M A Lebot, R Faroux, et al.
Page
of 3
Search research articles
Search
Showing results (21-30 of 27) with videos related to
Sort By:
Page
of 3
You have reached the last page of results.
This site can display upto 27 results.
ESMO Open
|
October 1, 2025
Pembrolizumab with trastuzumab and chemotherapy for HER2-positive advanced gastric cancer: health-related quality-of-life analysis from the randomized KEYNOTE-811 trial
Y Y Janjigian, A Kawazoe, J Xu, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 25, 2019
Continuation versus discontinuation of first-line chemotherapy in patients with metastatic squamous cell oesophageal cancer: A randomised phase II trial (E-DIS)
A Adenis, J Bennouna, P L Etienne, et al.
ESMO Open
|
February 26, 2026
Surrogate endpoints for survival in KEYNOTE-585: neoadjuvant/adjuvant pembrolizumab plus chemotherapy versus placebo plus chemotherapy for gastric or gastroesophageal junction adenocarcinoma
K Shitara, Y-J Bang, L S Wyrwicz, et al.
ESMO Open
|
November 19, 2025
Pembrolizumab plus chemotherapy versus chemotherapy for advanced esophageal cancer: 5-year extended follow-up for the randomized phase III KEYNOTE-590 study
J-P Metges, K Kato, J-M Sun, et al.
ESMO Open
|
December 3, 2025
Streptozotocin plus 5-fluorouracil followed by everolimus or the reverse sequence in patients with advanced pancreatic neuroendocrine tumors (SEQTOR-GETNE phase III study): a randomized clinical trial
J Capdevila, S Tafuto, M Krogh, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 5, 2017
Clinical validation of a prognostic tool in a population of outpatients treated for incurable cancer undergoing anticancer therapy: PRONOPALL study
H Bourgeois, F Grudé, P Solal-Céligny, et al.
Oncologie (Paris, France)
|
July 21, 2015
Evaluation in usual practice of the bevacizumab-FOLFIRI combination for the first-line treatment of patients with unresectable metastatic colorectal cancer treated in 2006: focus on resected patients and oncogeriatrics: AVASTIN OUEST cohort of the Observatory of Cancer of the Brittany and Pays de la Loire Areas (<i>Observatoire dédié au Cancer Bretagne / Pays de la Loire</i>)
J P Metges, M A Lebot, R Faroux, et al.
Page
of 3